View ValuationDecipher Labs 将来の成長Future 基準チェック /06現在、 Decipher Labsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Feb 14Third quarter 2026 earnings released: ₹0.53 loss per share (vs ₹0.59 loss in 3Q 2025)Third quarter 2026 results: ₹0.53 loss per share (improved from ₹0.59 loss in 3Q 2025). Revenue: ₹32.3m (down 46% from 3Q 2025). Net loss: ₹5.39m (loss narrowed 9.1% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 26% per year.お知らせ • Feb 09Decipher Labs Limited to Report Q3, 2026 Results on Feb 12, 2026Decipher Labs Limited announced that they will report Q3, 2026 results on Feb 12, 2026New Risk • Dec 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹65m free cash flow). Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹105.5m market cap, or US$1.17m). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Revenue is less than US$5m (₹176m revenue, or US$2.0m).Reported Earnings • Nov 15Second quarter 2026 earnings released: EPS: ₹0.02 (vs ₹1.31 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.02 (up from ₹1.31 loss in 2Q 2025). Revenue: ₹43.3m (down 28% from 2Q 2025). Net income: ₹201.0k (up ₹13.5m from 2Q 2025). Profit margin: 0.5% (up from net loss in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.お知らせ • Nov 11Decipher Labs Limited to Report Q2, 2026 Results on Nov 13, 2025Decipher Labs Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025お知らせ • Sep 08Decipher Labs Limited, Annual General Meeting, Sep 30, 2025Decipher Labs Limited, Annual General Meeting, Sep 30, 2025, at 11:00 Indian Standard Time.Reported Earnings • Aug 16First quarter 2026 earnings released: ₹3.39 loss per share (vs ₹0.94 profit in 1Q 2025)First quarter 2026 results: ₹3.39 loss per share (down from ₹0.94 profit in 1Q 2025). Revenue: ₹29.3m (down 61% from 1Q 2025). Net loss: ₹34.3m (down 462% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.お知らせ • Aug 12Decipher Labs Limited to Report Q1, 2026 Results on Aug 14, 2025Decipher Labs Limited announced that they will report Q1, 2026 results on Aug 14, 2025Reported Earnings • Jun 02Full year 2025 earnings released: ₹5.03 loss per share (vs ₹1.66 loss in FY 2024)Full year 2025 results: ₹5.03 loss per share (further deteriorated from ₹1.66 loss in FY 2024). Revenue: ₹239.3m (down 34% from FY 2024). Net loss: ₹50.8m (loss widened 203% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 15Third quarter 2025 earnings released: ₹0.59 loss per share (vs ₹0.01 profit in 3Q 2024)Third quarter 2025 results: ₹0.59 loss per share (down from ₹0.01 profit in 3Q 2024). Revenue: ₹59.7m (down 28% from 3Q 2024). Net loss: ₹5.93m (down ₹6.03m from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.お知らせ • Jan 02Decipher Labs Limited Appoints Preeti Singh as Company Secretary and Compliance Officer, with Effect from January 01, 2025The board of directors of Decipher Labs Limited at its meeting held on 31 December, 2024, Appointment of Ms. Preeti Singh as the Company Secretary and Compliance Officer of the Company with effect from January 01, 2025. Ms. Preeti Singh is a qualified Company Secretary and legal professional. She is having rich experience in Secretarial and legal works for 3 years.Reported Earnings • Nov 16Second quarter 2025 earnings released: ₹1.31 loss per share (vs ₹1.92 loss in 2Q 2024)Second quarter 2025 results: ₹1.31 loss per share (improved from ₹1.92 loss in 2Q 2024). Revenue: ₹59.9m (down 20% from 2Q 2024). Net loss: ₹13.3m (loss narrowed 32% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.お知らせ • Sep 26Decipher Labs Limited Announces Executive ChangesDecipher Labs Limited announced that the Mr. Siva Kumar Reddy Chappidi has resigned from the post of Company Secretary and Compliance Officer with effect from 30 September 2024 (post-closing hour) due to personal reasons. Mr. Sushant Mohan Lal, Executive Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer.お知らせ • Sep 04+ 2 more updatesDecipher Labs Limited to Report Q2, 2025 Results on Nov 14, 2024Decipher Labs Limited announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 20First quarter 2025 earnings released: EPS: ₹0.94 (vs ₹0.94 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.94 (up from ₹0.94 loss in 1Q 2024). Revenue: ₹74.4m (down 22% from 1Q 2024). Net income: ₹9.47m (up ₹18.9m from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.お知らせ • Aug 16Decipher Labs Limited, Annual General Meeting, Sep 30, 2024Decipher Labs Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time.お知らせ • Aug 09Decipher Labs Limited to Report Q1, 2025 Results on Aug 14, 2024Decipher Labs Limited announced that they will report Q1, 2025 results on Aug 14, 2024New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.8% per year over the past 5 years. Market cap is less than US$10m (₹180.2m market cap, or US$2.16m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹351m revenue, or US$4.2m).New Risk • Feb 16New major risk - Revenue and earnings growthEarnings have declined by 6.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.7% per year over the past 5 years. Market cap is less than US$10m (₹187.3m market cap, or US$2.26m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹280m revenue, or US$3.4m).Board Change • Oct 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Whole-Time Director Sushant Lal is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Sep 17Decipher Labs Limited Announces Executive ChangesMudunuru Limited announced that Mr. Pankaj Tulsayani has resigned from the post of Company Secretary and Compliance Officer of Decipher Labs Limited with effect from September 16, 2023 (After close of business hours). Mr. Madhusudan Raju Mudunuru, Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer.お知らせ • Sep 07+ 2 more updatesDecipher Labs Limited to Report Q4, 2024 Results on May 30, 2024Decipher Labs Limited announced that they will report Q4, 2024 results on May 30, 2024お知らせ • Sep 05+ 1 more updateDecipher Labs Limited, Annual General Meeting, Sep 30, 2023Decipher Labs Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time.New Risk • Aug 17New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₹356m (US$4.3m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹159.4m market cap, or US$1.92m). Minor Risk Revenue is less than US$5m (₹356m revenue, or US$4.3m).Reported Earnings • Aug 16First quarter 2024 earnings released: ₹0.94 loss per share (vs ₹5.85 profit in 1Q 2023)First quarter 2024 results: ₹0.94 loss per share (down from ₹5.85 profit in 1Q 2023). Revenue: ₹95.1m (down 25% from 1Q 2023). Net loss: ₹9.48m (down 116% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Aug 08Decipher Labs Limited to Report Q1, 2024 Results on Aug 14, 2023Decipher Labs Limited announced that they will report Q1, 2024 results on Aug 14, 2023お知らせ • Jul 22Decipher Labs Limited Announces Company Secretary and Compliance Officer ChangesDecipher Labs Limited at its board meeting held on July 19, 2023, resignation of Ms. Megha Agarwal as Company Secretary and Compliance Officer of the Company effective June 30, 2023, appointment of Mr. Siva Kumar Reddy Chappidi as Company Secretary and Compliance Officer of the Company effective July 19, 2023. Mr. C. Siva Kumar Reddy is a qualified Company Secretary and is having working knowledge in Secretarial matters.Reported Earnings • Jun 01Full year 2023 earnings released: ₹2.66 loss per share (vs ₹11.27 profit in FY 2022)Full year 2023 results: ₹2.66 loss per share (down from ₹11.27 profit in FY 2022). Revenue: ₹529.4m (down 19% from FY 2022). Net loss: ₹26.8m (down 124% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Feb 08Decipher Labs Limited to Report Q3, 2023 Results on Feb 14, 2023Decipher Labs Limited announced that they will report Q3, 2023 results on Feb 14, 2023Valuation Update With 7 Day Price Move • Dec 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹33.80, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹35.00, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 79% over the past three years.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹52.60, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 209% over the past three years.お知らせ • Aug 30Decipher Labs Limited, Annual General Meeting, Sep 29, 2022Decipher Labs Limited, Annual General Meeting, Sep 29, 2022, at 11:30 Indian Standard Time.Reported Earnings • Aug 18First quarter 2023 earnings released: EPS: ₹5.85 (vs ₹0.66 in 1Q 2022)First quarter 2023 results: EPS: ₹5.85 (up from ₹0.66 in 1Q 2022). Revenue: ₹194.8m (up 45% from 1Q 2022). Net income: ₹59.1m (up ₹52.4m from 1Q 2022). Profit margin: 30% (up from 5.0% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹49.00, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 124% over the past three years.お知らせ • Jul 30Decipher Labs Limited to Report Q1, 2023 Results on Aug 13, 2022Decipher Labs Limited announced that they will report Q1, 2023 results at 3:30 PM, Indian Standard Time on Aug 13, 2022Reported Earnings • May 18Full year 2022 earnings released: EPS: ₹11.27 (vs ₹1.39 in FY 2021)Full year 2022 results: EPS: ₹11.27 (up from ₹1.39 in FY 2021). Revenue: ₹730.0m (up 31% from FY 2021). Net income: ₹113.8m (up ₹99.8m from FY 2021). Profit margin: 16% (up from 2.5% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹43.30, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 67% over the past three years.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹61.75, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 138% over the past three years.Recent Insider Transactions • Mar 21CEO & Whole Time Director recently sold ₹421k worth of stockOn the 16th of March, Janakiram Ajjarapu sold around 6k shares on-market at roughly ₹67.30 per share. This was the largest sale by an insider in the last 3 months. This was Janakiram's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹62.00, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 173% over the past three years.Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹7.21 (up from ₹0.10 in 3Q 2021). Revenue: ₹210.2m (up 53% from 3Q 2021). Net income: ₹72.8m (up ₹71.8m from 3Q 2021). Profit margin: 35% (up from 0.8% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₹61.05, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 194% over the past three years.お知らせ • Feb 04Decipher Labs Limited to Report Q3, 2022 Results on Feb 14, 2022Decipher Labs Limited announced that they will report Q3, 2022 results on Feb 14, 2022Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹81.90, the stock trades at a trailing P/E ratio of 27.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 301% over the past three years.Valuation Update With 7 Day Price Move • Dec 02Investor sentiment improved over the past weekAfter last week's 57% share price gain to ₹59.95, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 153% over the past three years.Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹36.60, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 32% over the past three years.Reported Earnings • Jul 02Full year 2021 earnings releasedThe company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹562.1m (up 134% from FY 2020). Net income: ₹14.0m (up 27% from FY 2020). Profit margin: 2.5% (down from 4.6% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹42.10, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 58% over the past three years.Valuation Update With 7 Day Price Move • May 16Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.35, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 78% over the past three years.Valuation Update With 7 Day Price Move • Apr 30Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹31.80, the stock trades at a trailing P/E ratio of 24.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 26% over the past three years.Reported Earnings • Feb 15Third quarter 2021 earnings released: EPS ₹0.10The company reported a decent third quarter result with improved revenues, although earnings and profit margins were weaker. Third quarter 2021 results: Revenue: ₹137.8m (up 270% from 3Q 2020). Net income: ₹1.04m (down 60% from 3Q 2020). Profit margin: 0.8% (down from 7.0% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 07Decipher Labs Limited to Report Q3, 2021 Results on Feb 13, 2021Decipher Labs Limited announced that they will report Q3, 2021 results on Feb 13, 2021Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹35.20, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 21.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 76%.Is New 90 Day High Low • Dec 14New 90-day high: ₹29.10The company is up 29% from its price of ₹22.50 on 15 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 15% share price gain to ₹28.85, the stock is trading at a trailing P/E ratio of 21.8x, up from the previous P/E ratio of 18.9x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 44%.Is New 90 Day High Low • Nov 23New 90-day high: ₹26.05The company is up 3.0% from its price of ₹25.25 on 25 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 15% share price gain to ₹24.85, the stock is trading at a trailing P/E ratio of 18.8x, up from the previous P/E ratio of 16.3x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 24%.Reported Earnings • Nov 15Second quarter 2021 earnings released: EPS ₹0.31The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: ₹136.1m (up ₹123.8m from 2Q 2020). Net income: ₹3.09m (up ₹2.58m from 2Q 2020). Profit margin: 2.3% (down from 4.2% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 05Decipher Labs Limited to Report Q2, 2021 Results on Nov 12, 2020Decipher Labs Limited announced that they will report Q2, 2021 results on Nov 12, 2020お知らせ • Oct 02Decipher Labs Limited Approves Board ChangesDecipher Labs Limited at its board meeting held on October 1, 2020 approved the appointment of the Promoter of the company Mr. Janakiram Ajjarapu as an Additional Director (Executive Director) and Key Managerial Person of the Company with effect from October 01, 2020. Further, in compliance with the circulars issued by BSE Limited, the company confirmed that Mr. Janakiram Ajjarapu has not been debarred from holding the office of Director by virtue of any SEBI order or any other authority. Also, he is not related to any Director or Key Managerial Personnel. The company further announced that Mr. Vasudev Kommaraju, Director of the company did not seek re-appointment in the Annual General meeting held on 29th September, 2020 and has ceased to be a Director of the company.Is New 90 Day High Low • Sep 24New 90-day low: ₹19.20The company is down 27% from its price of ₹26.25 on 26 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.お知らせ • Aug 25Decipher Labs Limited to Report Q1, 2021 Results on Sep 01, 2020Decipher Labs Limited announced that they will report Q1, 2021 results on Sep 01, 2020お知らせ • Jun 20Decipher Labs Limited to Report Q4, 2020 Results on Jun 29, 2020Decipher Labs Limited announced that they will report Q4, 2020 results on Jun 29, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Decipher Labs は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:524752 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025149-81N/AN/AN/A9/30/2025176-81-65-65N/A6/30/2025193-95N/AN/AN/A3/31/2025239-51-99-98N/A12/31/20243042N/AN/AN/A9/30/20243278-21-20N/A6/30/20243442N/AN/AN/A3/31/2024363-174849N/A12/31/2023351-49N/AN/AN/A9/30/2023285-127-67-59N/A6/30/2023425-95N/AN/AN/A3/31/2023529-27-23-16N/A12/31/202259113N/AN/AN/A9/30/2022617163168170N/A6/30/2022645166N/AN/AN/A3/31/20226531148183N/A12/31/2021561102N/AN/AN/A9/30/202156230-92-90N/A6/30/202154719N/AN/AN/A3/31/2021556141518N/A12/31/202059113N/AN/AN/A9/30/202049015-79-76N/A6/30/202036812N/AN/AN/A3/31/202024011-154-152N/A12/31/2019765N/AN/AN/A9/30/2019454N/AN/AN/A6/30/2019464N/AN/AN/A3/31/2019814N/A2N/A12/31/2018724N/AN/AN/A9/30/2018693N/AN/AN/A6/30/2018583N/AN/AN/A3/31/2018102N/A-1N/A12/31/201771N/AN/AN/A9/30/201750N/AN/AN/A6/30/20174-2N/AN/AN/A3/31/20174-2N/A0N/A12/31/20163-10N/AN/AN/A9/30/20163-9N/AN/AN/A6/30/20162-13N/AN/AN/A3/31/20162-13N/A-3N/A12/31/20152-28N/AN/AN/A9/30/20151-40N/AN/AN/A6/30/20151-37N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 524752の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 524752の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 524752の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 524752の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 524752の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 524752の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 22:59終値2026/05/22 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Decipher Labs Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Feb 14Third quarter 2026 earnings released: ₹0.53 loss per share (vs ₹0.59 loss in 3Q 2025)Third quarter 2026 results: ₹0.53 loss per share (improved from ₹0.59 loss in 3Q 2025). Revenue: ₹32.3m (down 46% from 3Q 2025). Net loss: ₹5.39m (loss narrowed 9.1% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 26% per year.
お知らせ • Feb 09Decipher Labs Limited to Report Q3, 2026 Results on Feb 12, 2026Decipher Labs Limited announced that they will report Q3, 2026 results on Feb 12, 2026
New Risk • Dec 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹65m free cash flow). Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹105.5m market cap, or US$1.17m). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Revenue is less than US$5m (₹176m revenue, or US$2.0m).
Reported Earnings • Nov 15Second quarter 2026 earnings released: EPS: ₹0.02 (vs ₹1.31 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.02 (up from ₹1.31 loss in 2Q 2025). Revenue: ₹43.3m (down 28% from 2Q 2025). Net income: ₹201.0k (up ₹13.5m from 2Q 2025). Profit margin: 0.5% (up from net loss in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 11Decipher Labs Limited to Report Q2, 2026 Results on Nov 13, 2025Decipher Labs Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025
お知らせ • Sep 08Decipher Labs Limited, Annual General Meeting, Sep 30, 2025Decipher Labs Limited, Annual General Meeting, Sep 30, 2025, at 11:00 Indian Standard Time.
Reported Earnings • Aug 16First quarter 2026 earnings released: ₹3.39 loss per share (vs ₹0.94 profit in 1Q 2025)First quarter 2026 results: ₹3.39 loss per share (down from ₹0.94 profit in 1Q 2025). Revenue: ₹29.3m (down 61% from 1Q 2025). Net loss: ₹34.3m (down 462% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 12Decipher Labs Limited to Report Q1, 2026 Results on Aug 14, 2025Decipher Labs Limited announced that they will report Q1, 2026 results on Aug 14, 2025
Reported Earnings • Jun 02Full year 2025 earnings released: ₹5.03 loss per share (vs ₹1.66 loss in FY 2024)Full year 2025 results: ₹5.03 loss per share (further deteriorated from ₹1.66 loss in FY 2024). Revenue: ₹239.3m (down 34% from FY 2024). Net loss: ₹50.8m (loss widened 203% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 15Third quarter 2025 earnings released: ₹0.59 loss per share (vs ₹0.01 profit in 3Q 2024)Third quarter 2025 results: ₹0.59 loss per share (down from ₹0.01 profit in 3Q 2024). Revenue: ₹59.7m (down 28% from 3Q 2024). Net loss: ₹5.93m (down ₹6.03m from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 02Decipher Labs Limited Appoints Preeti Singh as Company Secretary and Compliance Officer, with Effect from January 01, 2025The board of directors of Decipher Labs Limited at its meeting held on 31 December, 2024, Appointment of Ms. Preeti Singh as the Company Secretary and Compliance Officer of the Company with effect from January 01, 2025. Ms. Preeti Singh is a qualified Company Secretary and legal professional. She is having rich experience in Secretarial and legal works for 3 years.
Reported Earnings • Nov 16Second quarter 2025 earnings released: ₹1.31 loss per share (vs ₹1.92 loss in 2Q 2024)Second quarter 2025 results: ₹1.31 loss per share (improved from ₹1.92 loss in 2Q 2024). Revenue: ₹59.9m (down 20% from 2Q 2024). Net loss: ₹13.3m (loss narrowed 32% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 26Decipher Labs Limited Announces Executive ChangesDecipher Labs Limited announced that the Mr. Siva Kumar Reddy Chappidi has resigned from the post of Company Secretary and Compliance Officer with effect from 30 September 2024 (post-closing hour) due to personal reasons. Mr. Sushant Mohan Lal, Executive Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer.
お知らせ • Sep 04+ 2 more updatesDecipher Labs Limited to Report Q2, 2025 Results on Nov 14, 2024Decipher Labs Limited announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 20First quarter 2025 earnings released: EPS: ₹0.94 (vs ₹0.94 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.94 (up from ₹0.94 loss in 1Q 2024). Revenue: ₹74.4m (down 22% from 1Q 2024). Net income: ₹9.47m (up ₹18.9m from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 16Decipher Labs Limited, Annual General Meeting, Sep 30, 2024Decipher Labs Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time.
お知らせ • Aug 09Decipher Labs Limited to Report Q1, 2025 Results on Aug 14, 2024Decipher Labs Limited announced that they will report Q1, 2025 results on Aug 14, 2024
New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.8% per year over the past 5 years. Market cap is less than US$10m (₹180.2m market cap, or US$2.16m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹351m revenue, or US$4.2m).
New Risk • Feb 16New major risk - Revenue and earnings growthEarnings have declined by 6.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.7% per year over the past 5 years. Market cap is less than US$10m (₹187.3m market cap, or US$2.26m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹280m revenue, or US$3.4m).
Board Change • Oct 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Whole-Time Director Sushant Lal is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 17Decipher Labs Limited Announces Executive ChangesMudunuru Limited announced that Mr. Pankaj Tulsayani has resigned from the post of Company Secretary and Compliance Officer of Decipher Labs Limited with effect from September 16, 2023 (After close of business hours). Mr. Madhusudan Raju Mudunuru, Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer.
お知らせ • Sep 07+ 2 more updatesDecipher Labs Limited to Report Q4, 2024 Results on May 30, 2024Decipher Labs Limited announced that they will report Q4, 2024 results on May 30, 2024
お知らせ • Sep 05+ 1 more updateDecipher Labs Limited, Annual General Meeting, Sep 30, 2023Decipher Labs Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time.
New Risk • Aug 17New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₹356m (US$4.3m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹159.4m market cap, or US$1.92m). Minor Risk Revenue is less than US$5m (₹356m revenue, or US$4.3m).
Reported Earnings • Aug 16First quarter 2024 earnings released: ₹0.94 loss per share (vs ₹5.85 profit in 1Q 2023)First quarter 2024 results: ₹0.94 loss per share (down from ₹5.85 profit in 1Q 2023). Revenue: ₹95.1m (down 25% from 1Q 2023). Net loss: ₹9.48m (down 116% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Aug 08Decipher Labs Limited to Report Q1, 2024 Results on Aug 14, 2023Decipher Labs Limited announced that they will report Q1, 2024 results on Aug 14, 2023
お知らせ • Jul 22Decipher Labs Limited Announces Company Secretary and Compliance Officer ChangesDecipher Labs Limited at its board meeting held on July 19, 2023, resignation of Ms. Megha Agarwal as Company Secretary and Compliance Officer of the Company effective June 30, 2023, appointment of Mr. Siva Kumar Reddy Chappidi as Company Secretary and Compliance Officer of the Company effective July 19, 2023. Mr. C. Siva Kumar Reddy is a qualified Company Secretary and is having working knowledge in Secretarial matters.
Reported Earnings • Jun 01Full year 2023 earnings released: ₹2.66 loss per share (vs ₹11.27 profit in FY 2022)Full year 2023 results: ₹2.66 loss per share (down from ₹11.27 profit in FY 2022). Revenue: ₹529.4m (down 19% from FY 2022). Net loss: ₹26.8m (down 124% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Feb 08Decipher Labs Limited to Report Q3, 2023 Results on Feb 14, 2023Decipher Labs Limited announced that they will report Q3, 2023 results on Feb 14, 2023
Valuation Update With 7 Day Price Move • Dec 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹33.80, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹35.00, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 79% over the past three years.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹52.60, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 209% over the past three years.
お知らせ • Aug 30Decipher Labs Limited, Annual General Meeting, Sep 29, 2022Decipher Labs Limited, Annual General Meeting, Sep 29, 2022, at 11:30 Indian Standard Time.
Reported Earnings • Aug 18First quarter 2023 earnings released: EPS: ₹5.85 (vs ₹0.66 in 1Q 2022)First quarter 2023 results: EPS: ₹5.85 (up from ₹0.66 in 1Q 2022). Revenue: ₹194.8m (up 45% from 1Q 2022). Net income: ₹59.1m (up ₹52.4m from 1Q 2022). Profit margin: 30% (up from 5.0% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹49.00, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 124% over the past three years.
お知らせ • Jul 30Decipher Labs Limited to Report Q1, 2023 Results on Aug 13, 2022Decipher Labs Limited announced that they will report Q1, 2023 results at 3:30 PM, Indian Standard Time on Aug 13, 2022
Reported Earnings • May 18Full year 2022 earnings released: EPS: ₹11.27 (vs ₹1.39 in FY 2021)Full year 2022 results: EPS: ₹11.27 (up from ₹1.39 in FY 2021). Revenue: ₹730.0m (up 31% from FY 2021). Net income: ₹113.8m (up ₹99.8m from FY 2021). Profit margin: 16% (up from 2.5% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹43.30, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 67% over the past three years.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹61.75, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 138% over the past three years.
Recent Insider Transactions • Mar 21CEO & Whole Time Director recently sold ₹421k worth of stockOn the 16th of March, Janakiram Ajjarapu sold around 6k shares on-market at roughly ₹67.30 per share. This was the largest sale by an insider in the last 3 months. This was Janakiram's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹62.00, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 173% over the past three years.
Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹7.21 (up from ₹0.10 in 3Q 2021). Revenue: ₹210.2m (up 53% from 3Q 2021). Net income: ₹72.8m (up ₹71.8m from 3Q 2021). Profit margin: 35% (up from 0.8% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₹61.05, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 194% over the past three years.
お知らせ • Feb 04Decipher Labs Limited to Report Q3, 2022 Results on Feb 14, 2022Decipher Labs Limited announced that they will report Q3, 2022 results on Feb 14, 2022
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹81.90, the stock trades at a trailing P/E ratio of 27.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 301% over the past three years.
Valuation Update With 7 Day Price Move • Dec 02Investor sentiment improved over the past weekAfter last week's 57% share price gain to ₹59.95, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 153% over the past three years.
Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹36.60, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 32% over the past three years.
Reported Earnings • Jul 02Full year 2021 earnings releasedThe company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹562.1m (up 134% from FY 2020). Net income: ₹14.0m (up 27% from FY 2020). Profit margin: 2.5% (down from 4.6% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹42.10, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 58% over the past three years.
Valuation Update With 7 Day Price Move • May 16Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.35, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 78% over the past three years.
Valuation Update With 7 Day Price Move • Apr 30Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹31.80, the stock trades at a trailing P/E ratio of 24.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 26% over the past three years.
Reported Earnings • Feb 15Third quarter 2021 earnings released: EPS ₹0.10The company reported a decent third quarter result with improved revenues, although earnings and profit margins were weaker. Third quarter 2021 results: Revenue: ₹137.8m (up 270% from 3Q 2020). Net income: ₹1.04m (down 60% from 3Q 2020). Profit margin: 0.8% (down from 7.0% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 07Decipher Labs Limited to Report Q3, 2021 Results on Feb 13, 2021Decipher Labs Limited announced that they will report Q3, 2021 results on Feb 13, 2021
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹35.20, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 21.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 76%.
Is New 90 Day High Low • Dec 14New 90-day high: ₹29.10The company is up 29% from its price of ₹22.50 on 15 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 15% share price gain to ₹28.85, the stock is trading at a trailing P/E ratio of 21.8x, up from the previous P/E ratio of 18.9x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 44%.
Is New 90 Day High Low • Nov 23New 90-day high: ₹26.05The company is up 3.0% from its price of ₹25.25 on 25 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 15% share price gain to ₹24.85, the stock is trading at a trailing P/E ratio of 18.8x, up from the previous P/E ratio of 16.3x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 24%.
Reported Earnings • Nov 15Second quarter 2021 earnings released: EPS ₹0.31The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: ₹136.1m (up ₹123.8m from 2Q 2020). Net income: ₹3.09m (up ₹2.58m from 2Q 2020). Profit margin: 2.3% (down from 4.2% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 05Decipher Labs Limited to Report Q2, 2021 Results on Nov 12, 2020Decipher Labs Limited announced that they will report Q2, 2021 results on Nov 12, 2020
お知らせ • Oct 02Decipher Labs Limited Approves Board ChangesDecipher Labs Limited at its board meeting held on October 1, 2020 approved the appointment of the Promoter of the company Mr. Janakiram Ajjarapu as an Additional Director (Executive Director) and Key Managerial Person of the Company with effect from October 01, 2020. Further, in compliance with the circulars issued by BSE Limited, the company confirmed that Mr. Janakiram Ajjarapu has not been debarred from holding the office of Director by virtue of any SEBI order or any other authority. Also, he is not related to any Director or Key Managerial Personnel. The company further announced that Mr. Vasudev Kommaraju, Director of the company did not seek re-appointment in the Annual General meeting held on 29th September, 2020 and has ceased to be a Director of the company.
Is New 90 Day High Low • Sep 24New 90-day low: ₹19.20The company is down 27% from its price of ₹26.25 on 26 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.
お知らせ • Aug 25Decipher Labs Limited to Report Q1, 2021 Results on Sep 01, 2020Decipher Labs Limited announced that they will report Q1, 2021 results on Sep 01, 2020
お知らせ • Jun 20Decipher Labs Limited to Report Q4, 2020 Results on Jun 29, 2020Decipher Labs Limited announced that they will report Q4, 2020 results on Jun 29, 2020